Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C brings $30mm to Epic Sciences

Executive Summary

Epic Sciences Inc. (molecular diagnostics for cancer) closed a $30mm Series C round. New investors RusnanoMedInvest and Arcus Ventures participated, along with returning backers Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, along with undisclosed individuals. Proceeds will fund commercialization of Epic's circulating rare cell analysis platform, which has the ability to detect one circulating tumor cell out of 50bn cells and aids in the minimally invasive characterization of protein biomarker and genomic profiles.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies